BioSpace News Archive

FUJIFILM Medical Systems U.S.A., Inc., a leading provider of diagnostic imaging and medical informatics solutions, will provide an unrestricted educational grant to host a continuing medical education program titled “Encourage Your Patient to Be Fearless” on June 12, 2019 from 5:30 – 8:00 PM at 1100 SE Waverly Drive in Portland, Oregon.

TransPerfect Life Sciences, a leading provider of services and technologies to support global product development for the life sciences industry, today announced highlights of its upcoming presence at DIA 2019, including a workshop entitled “Setting the Stage for Effective Stakeholder Collaboration,” as well as live demos of the award-winning Trial Interactive e-clinical platform.

The following is a statement by Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA), on the Final Report of the Advisory Council on the Implementation of National Pharmacare

Neptune began commercial production and shipping of cannabis extracts during the last weeks of the fourth quarter, recording its first cannabis revenues.

Universal Health Realty Income Trust announced that its Board of Trustees voted to increase the quarterly dividend by $.005 and pay a dividend of $.68 per share on July 2, 2019 to shareholders of record as of June 24, 2019

Health Canada is advising Canadians of a labelling error affecting one lot of Linessa 28 birth control pills on the Canadian market (lot 190056, expiry 06/2021).

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Raymond James Life Sciences and MedTech Conference taking place June 18-19, 2019 in New York, NY.

Dietary supplementation with BioCell Collagen® significantly reduced facial lines and wrinkles, crow’s feet lines/wrinkles, increased skin elasticity and cutaneous collagen content, and decreased skin dryness compared to placebo.

Tolero Pharmaceuticals, Inc. announced that the first patient has been dosed in a Phase 1/2 study evaluating the investigational agent TP-0903, an AXL receptor tyrosine kinase inhibitor, in patients with previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma.

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the JMP Securities Life Sciences Conference